KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) EBITDA Margin (2019 - 2026)

Esperion Therapeutics filings provide 7 years of EBITDA Margin readings, the most recent being 36.71% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 6755.0% to 36.71% in Q4 2025 year-over-year; TTM through Dec 2025 was 5.63%, a 994.0% increase, with the full-year FY2025 number at 5.63%, up 994.0% from a year prior.
  • EBITDA Margin hit 36.71% in Q4 2025 for Esperion Therapeutics, up from 35.89% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 44.3% in Q1 2024 to a low of 1139.82% in Q1 2021.
  • Median EBITDA Margin over the past 5 years was 148.07% (2023), compared with a mean of 216.9%.
  • Biggest five-year swings in EBITDA Margin: soared 311360bps in 2021 and later tumbled -24480bps in 2022.
  • Esperion Therapeutics' EBITDA Margin stood at 423.02% in 2021, then surged by 30bps to 294.38% in 2022, then skyrocketed by 41bps to 174.71% in 2023, then skyrocketed by 82bps to 30.85% in 2024, then soared by 219bps to 36.71% in 2025.
  • The last three reported values for EBITDA Margin were 36.71% (Q4 2025), 35.89% (Q3 2025), and 15.45% (Q2 2025) per Business Quant data.